In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|May 23, 2018
WuXi Biologics to Invest $60 Million in New Singapore Biomanufacturing Facility
Author(s)BioPharm International Editors
WuXi Biologics will build a biologics manufacturing facility in Singapore that will use both fed-batch and continuous perfusion-based single-use bioreactors.
Advertisement
WuXi Biologics announced on May 22, 2018 that it will invest S$80 million (approximately US$60 million) and hire approximately 150 employees to establish a biologics manufacturing facility in Singapore. The facility will be the company’s tenth global drug substance manufacturing facility, its second site outside of China, and its first in Asia outside of China. The company is headquartered in Wuxi city, Jiangsu province, China.
This “facility of the future” will be built upon a new approach WuXi Biologics has pioneered deploying single-use bioreactors. A total of approximately 4500-L bioreactor capacity will be installed with two, 2000-L traditional fed-batch and one, 500-L perfusion-based continuous processing bioreactors. The facility will be able to handle both clinical and small-volume commercial production. The company will also build an early-stage bioprocess development laboratory.
“Singapore is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. With the strong support, we believe we can quickly push forward this exciting project,” said Dr. Ge Li, chairman of WuXi Biologics, in the press release.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5